Table 1 Demographic profile of population.

From: Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT

  

Donor

    
 

Group

MSD

 

HD

 

p

  

Missing

N (%)

Missing

N (%)

 

Total

  

1414 (77.3%)

 

415 (22.7%)

 

Donor age (years)

Median (IQR)

369 (26.1%)

55.6 (49–62.2)

57 (13.7%)

36.7 (29.4–46.8)

<0.001

Patient age (years)

Median (IQR)

 

57.9 (49.9–63.6)

 

60.9 (52.2–66.2)

0.001

Patient sex

Male

 

869 (61.5%)

 

269 (64.8%)

0.2

 

Female

 

545 (38.5%)

 

146 (35.2%)

 

Sex match

Female to male

12 (0.8%)

410 (29.2%)

 

85 (20.5%)

0.001

 

Other combinations

 

992 (70.8%)

 

330 (79.5%)

 

WHO classification

RA/RARS/del5q

62 (4.4%)

74 (5.5%)

26 (6.3%)

13 (3.3%)

<0.001

 

RCMD-(RS)

 

210 (15.5%)

 

45 (11.6%)

 
 

RAEB-1

 

260 (19.2%)

 

53 (13.6%)

 
 

RAEB-2

 

446 (33%)

 

154 (39.6%)

 
 

Transformed to AML

 

244 (18%)

 

96 (24.7%)

 
 

MDS Unclassifiable

 

118 (8.7%)

 

28 (7.2%)

 

Interval diagnosis-HCT

Median (IQR)

 

7.8 (4.6–16.7)

 

11.6 (6.1–24.8)

0.002

Disease status at HCT

CR

68 (4.8%)

446 (33.1%)

16 (3.9%)

109 (27.3%)

<0.001

 

no CR

 

532 (39.5%)

 

213 (53.4%)

 
 

Untreated

 

368 (27.3%)

 

77 (19.3%)

 

Stem cell source

BM

 

127 (9%)

 

160 (38.6%)

<0.001

 

PB

 

1272 (90%)

 

254 (61.2%)

 
 

BM + PB

 

15 (1.1%)

 

1 (0.2%)

 

Infused CD34 (106/Kg)

Median (IQR)

935 (66.1%)

5 (3.6–6.7)

261 (62.9%)

5 (3.4-6.7)

0.3

CMV serostatus patient

Negative

27 (1.9%)

422 (30.4%)

6 (1.4%)

97 (23.7%)

0.01

 

Positive

 

965 (69.6%)

 

312 (76.3%)

 

Conditioning intensity

Standard

17 (1.2%)

582 (41.7%)

2 (0.5%)

199 (48.2%)

0.022

 

Reduced

 

815 (58.3%)

 

214 (51.8%)

 

TBI

No

16 (1.1%)

1250 (89.4%)

2 (0.5%)

319 (77.2%)

<0.001

 

Yes

 

148 (10.6%)

 

94 (22.8%)

 

In-vivo T cell depletion*

No

2 (0.1%)

768 (54.4%)

 

378 (91.1%)

<0.001

 

Yes

 

644 (45.6%)

 

37 (8.9%)

 

ATG

No

2 (0.1%)

877 (62.1%)

 

378 (91.1%)

<0.001

 

Yes

 

535 (37.9%)

 

37 (8.9%)

 

Alemtuzumab

No

2 (0.1%)

1303 (92.3%)

 

415 (100%)

<0.001

 

Yes

 

109 (7.7%)

   

PTCy

No

33 (2.3%)

1324 (95.9%)

  

<0.001

 

Yes

 

57 (4.1%)

 

415 (100%)

 

Karnofsky score

<90

89 (6.3%)

383 (28.9%)

20 (4.8%)

137 (34.7%)

0.033

 

90–100

 

942 (71.1%)

 

258 (65.3%)

 
  1. MSD matched sibling donor, CR complete remission, haplo haploidentical donors, TBI total body irradiation, PTCY post-transplant cyclophosphamide, ATG anti-thymocyte globulin, IQR interquartile range, HSCT Haematopoeitic stem cell transplant, CMV cytomegalovirus, BM bone marrow, PB peripheral blood, PB peripheral blood *In vivo T cell depletion excluding PTCY.
Back to article page